Success, complication, and mortality rates of initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
12 2022
Historique:
received: 11 03 2022
revised: 09 06 2022
accepted: 20 06 2022
pubmed: 22 8 2022
medline: 24 11 2022
entrez: 21 8 2022
Statut: ppublish

Résumé

The patients with unresectable perihilar cholangiocarcinoma require biliary drainage to relieve symptoms and allow for palliative systemic chemotherapy. The aim of this study was to establish the success, complication, and mortality rates of the initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma at presentation. In this retrospective multicenter study, patients with unresectable perihilar cholangiocarcinoma who underwent initial endoscopic or percutaneous transhepatic biliary drainage between 2002 and 2014 were included. The success of drainage was defined as a successful biliary stent or drain placement, no unscheduled reintervention within 14 days, and serum bilirubin levels <50 μmol/L (ie, 2.9 mg/dL) or a >50% decrease in serum bilirubin after 14 days. Severe complications, and 90-day mortality were recorded. Included were 186 patients: 161 (87%) underwent initial endoscopic biliary drainage and 25 (13%) underwent initial percutaneous transhepatic biliary drainage. The success of initial drainage was observed in 73 patients (45%) after endoscopic biliary drainage and 6 (24%) after percutaneous transhepatic biliary drainage. The reasons for an unsuccessful initial drainage were: the failure to place a drain or stent in 39 patients (21%), an unplanned reintervention within 14 days in 52 patients (28%), and the bilirubin level >50 μmol/L (or not halved) after 14 days of initial drainage in 16 patients (9%). Severe drainage-related complications occurred in 19 patients (12%) after endoscopic biliary drainage and in 3 (12%) after percutaneous transhepatic biliary drainage. Overall, 66 patients (36%) died within 90 days after initial biliary drainage. Initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma had a success rate of 45% and a 90-day mortality rate of 36%. Future studies for patients with perihilar cholangiocarcinoma should focus on improving biliary drainage.

Sections du résumé

BACKGROUND
The patients with unresectable perihilar cholangiocarcinoma require biliary drainage to relieve symptoms and allow for palliative systemic chemotherapy. The aim of this study was to establish the success, complication, and mortality rates of the initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma at presentation.
METHODS
In this retrospective multicenter study, patients with unresectable perihilar cholangiocarcinoma who underwent initial endoscopic or percutaneous transhepatic biliary drainage between 2002 and 2014 were included. The success of drainage was defined as a successful biliary stent or drain placement, no unscheduled reintervention within 14 days, and serum bilirubin levels <50 μmol/L (ie, 2.9 mg/dL) or a >50% decrease in serum bilirubin after 14 days. Severe complications, and 90-day mortality were recorded.
RESULTS
Included were 186 patients: 161 (87%) underwent initial endoscopic biliary drainage and 25 (13%) underwent initial percutaneous transhepatic biliary drainage. The success of initial drainage was observed in 73 patients (45%) after endoscopic biliary drainage and 6 (24%) after percutaneous transhepatic biliary drainage. The reasons for an unsuccessful initial drainage were: the failure to place a drain or stent in 39 patients (21%), an unplanned reintervention within 14 days in 52 patients (28%), and the bilirubin level >50 μmol/L (or not halved) after 14 days of initial drainage in 16 patients (9%). Severe drainage-related complications occurred in 19 patients (12%) after endoscopic biliary drainage and in 3 (12%) after percutaneous transhepatic biliary drainage. Overall, 66 patients (36%) died within 90 days after initial biliary drainage.
CONCLUSION
Initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma had a success rate of 45% and a 90-day mortality rate of 36%. Future studies for patients with perihilar cholangiocarcinoma should focus on improving biliary drainage.

Identifiants

pubmed: 35989132
pii: S0039-6060(22)00494-9
doi: 10.1016/j.surg.2022.06.028
pii:
doi:

Substances chimiques

Bilirubin RFM9X3LJ49

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1606-1613

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Anne-Marleen van Keulen (AV)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Marcia P Gaspersz (MP)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Jeroen L A van Vugt (JLA)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Eva Roos (E)

Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, the Netherlands.

Pim B Olthof (PB)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Robert J S Coelen (RJS)

Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, the Netherlands.

Marco J Bruno (MJ)

Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Lydi M J W van Driel (LMJW)

Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Rogier P Voermans (RP)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam Gastroenterology and Metabolism Institute, the Netherlands.

Casper H J van Eijck (CHJ)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Jeanin E van Hooft (JE)

Department of Gastroenterology and Hepatology, Leiden University Medical Center, the Netherlands.

Krijn P van Lienden (KP)

Department of Radiology, Amsterdam University Medical Center, the Netherlands.

Jeroen de Jonge (J)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Wojciech G Polak (WG)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Jan-Werner Poley (JW)

Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Chulja J Pek (CJ)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Adriaan Moelker (A)

Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

François E J A Willemssen (FEJA)

Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Thomas M van Gulik (TM)

Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, the Netherlands.

Joris I Erdmann (JI)

Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, the Netherlands.

L Hol (L)

Department of Gastroenterology and Hepatology, Maasstad Ziekenhuis, Rotterdam, the Netherlands.

Jan N M IJzermans (JNM)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Stefan Büttner (S)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: b.grootkoerkamp@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH